Return to Main Menu
Tool discovered to detect bladder
Foundation for Research and Development announced a promising new
diagnostic tool to detect and monitor bladder cancer.
Current tests for bladder cancer have shown to be accurate for only 40
percent of diagnoses. MUSC’s new test has demonstrated 90 percent
accuracy (100 percent specificity) in urine samples of patients with
various degrees of bladder cancer, confirming a newly discovered cell
receptor’s efficacy in diagnosing that cancer. The new cell receptor is
found on cancerous cells. When the receptor sloughs off the cancer
cells, it can be found in urine and prostatic fluid (in men). The
receptor offers great potential as a non-invasive, easy-to-make
dipstick or rapid urine test that could transform the screening and
diagnosis process for bladder cancer. The receptor was discovered by
MUSC’s Omar Moussa, Ph.D., Dennis Watson, Ph.D., and Perry Halushka,
Survival and treatment of bladder cancer is largely dependent on its
stage at the time of diagnosis. A test that would detect the disease
early would be of great significance, in addition to providing a new
alternative to invasive, costly and sometimes painful cystoscopies and
Patients undergo bladder cancer screening if they are determined to
have certain risk factors, including a previous diagnosis of bladder
cancer, birth defects of the bladder, advanced age (55 and older), or
work-related exposure to certain chemicals. Bladder cancer affects
males more than women, as well as more whites than other ethnicities,
according to the American Cancer Society. The organization estimates
that of the approximately 69,000 new bladder cancer cases in the U.S.
this year, almost 52,000 will be in men. Current studies report that
patients with successfully treated bladder cancer still have a 50
percent to 80 percent recurrence rate, making this potential
urine-based test perfect for home cancer recurrence monitoring. For the
methods most routinely used to detect or monitor bladder cancer,
convenience, comfort-ability and pain are issues related to
patients’ experiences with those tests.
For information regarding industry opportunities for this technology,
contact Ryan Fiorini, Ph.D., at 876-1906, or email@example.com.
Additional informa-tion regarding other revolutionary technologies and
scientific breakthroughs can be found on http://frd.musc.edu.
Friday, March 21, 2008
Catalyst Online is published weekly,
as needed and improved from time to time by the MUSC Office of Public
for the faculty, employees and students of the Medical University of
Carolina. Catalyst Online editor, Kim Draughn, can be reached at
or by email, firstname.lastname@example.org. Editorial copy can be submitted to
Online and to The Catalyst in print by fax, 792-6723, or by email to
email@example.com. To place an ad in The Catalyst hardcopy, call Island
Publications at 849-1778, ext. 201.